Compared to FLT3 wildtype NK-AML (AML 1–4), the FLT3-ITD positive NK-AML (AML 5–8) appeared to be more susceptible to trametinib (Figure 4D), and less susceptible to S63845 (Figure 4E). The gene discussed is FLT3; the disease is acute myeloid leukemia.